Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Melanoma 3Ovarian Neoplasms 2Breast Neoplasms 2Zollinger-Ellison Syndrome 1Waldenstrom Macroglobulinemia 1Vipoma 1Testicular Neoplasms 1Somatostatinoma 1Skin Neoplasms 1Sezary Syndrome 1Renal Insufficiency 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pheochromocytoma 1Non functioning pancreatic endocrine tumor 1Neuroendocrine Tumors 1Neoplasms, Unknown Primary 1Neoplasm Metastasis 1Mycosis Fungoides 1Multiple Myeloma 1Multiple Endocrine Neoplasia Type 2b 1Multiple Endocrine Neoplasia Type 2a 1Multiple Endocrine Neoplasia Type 1 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

veliparib 1cixutumumab 1Temozolomide 1Salts 1Octreotide 1Everolimus 1Capecitabine 1Acetates 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Zollinger-Ellison Syndrome × veliparib × Dermatologic × Clear all
NCT02831179 2017-09-28

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

Vanderbilt-Ingram Cancer Center

Phase 1 Withdrawn
DermatologicEndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adrenal Cortex Neoplasms, Carcinoid Tumor, Vipoma, Glucagonoma, Insulinoma, Pheochromocytoma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2a, Multiple Endocrine Neoplasia Type 2b

Data powered by HemOnc (CC BY 4.0) Colophon âš¡